Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India Liberalizes Foreign Investments But Will The Money Flow?

Executive Summary

India has eased foreign direct investment (FDI) norms in the pharmaceutical sector – reforms that are expected to buoy foreign capital inflows and investor sentiment, especially private equity, though some opponents claim it may potentially have a dire impact on India's future medicines security.

You may also be interested in...

Indian foreign investment debate hots up

The Indian pharma foreign direct investment (FDI) debate – something of a dormant volcano – erupted again toward the fag end of 2014, after a Parliamentary panel took a tough view on such inflows in the case of brownfield deals, only to be followed by reports of the finance ministry seemingly singing a different tune.

Mixed reactions to dilution of Indian brownfield FDI non-compete rider

India has diluted the rider concerning non-compete clauses in brownfield foreign direct investment (FDI) proposals, a move that has evoked mixed responses with some industry experts suggesting that it opens the door to discretionary decision-making and reflects an absence of clear policy outlook.

Indian blanket brownfield ban call brings fresh headwinds for FDI

An Indian Parliamentary panel has recommended a "blanket ban" on foreign direct investment (FDI) in brownfield pharmaceutical projects in the country, claiming "danger" to health and intellectual property rights aspects arising from such investments including access and affordability of medicines, as well as the "elbowing" out of the domestic industry and undue pressures on TRIPS arrangements.


Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts